ID18382A - PHARMACEUTICAL COMPOSITION AND METHODS FOR TREATMENT OF COMPULSIF DISORDERS USING NAALADASE INHIBITORS - Google Patents

PHARMACEUTICAL COMPOSITION AND METHODS FOR TREATMENT OF COMPULSIF DISORDERS USING NAALADASE INHIBITORS

Info

Publication number
ID18382A
ID18382A IDP972763A ID972763A ID18382A ID 18382 A ID18382 A ID 18382A ID P972763 A IDP972763 A ID P972763A ID 972763 A ID972763 A ID 972763A ID 18382 A ID18382 A ID 18382A
Authority
ID
Indonesia
Prior art keywords
compulsif
disorders
treatment
methods
pharmaceutical composition
Prior art date
Application number
IDP972763A
Other languages
Indonesian (id)
Inventor
Barbara S Slusher
Paul F Jackson
Kevin L Tays
Keith M Maclin
Original Assignee
Guilford Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/718,703 external-priority patent/US5824662A/en
Priority claimed from US08/775,586 external-priority patent/US5795877A/en
Priority claimed from US08/778,733 external-priority patent/US5863536A/en
Priority claimed from US08/825,997 external-priority patent/US5962521A/en
Priority claimed from US08/835,572 external-priority patent/US5902817A/en
Priority claimed from US08/842,360 external-priority patent/US6054444A/en
Priority claimed from US08/863,624 external-priority patent/US6046180A/en
Priority claimed from US08/858,985 external-priority patent/US6025344A/en
Priority claimed from US08/884,479 external-priority patent/US6017903A/en
Application filed by Guilford Pharm Inc filed Critical Guilford Pharm Inc
Publication of ID18382A publication Critical patent/ID18382A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/301—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3826—Acyclic unsaturated acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IDP972763A 1996-09-27 1997-08-08 PHARMACEUTICAL COMPOSITION AND METHODS FOR TREATMENT OF COMPULSIF DISORDERS USING NAALADASE INHIBITORS ID18382A (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US08/718,703 US5824662A (en) 1996-09-27 1996-09-27 Treatment of global and focal ischemia using naaladase inhibitors
US08/775,586 US5795877A (en) 1996-12-31 1996-12-31 Inhibitors of NAALADase enzyme activity
US08/778,733 US5863536A (en) 1996-12-31 1996-12-31 Phosphoramidate derivatives
US08/825,997 US5962521A (en) 1997-04-04 1997-04-04 Hydroxamic acid derivatives
US08/835,572 US5902817A (en) 1997-04-09 1997-04-09 Certain sulfoxide and sulfone derivatives
US08/842,360 US6054444A (en) 1997-04-24 1997-04-24 Phosphonic acid derivatives
US08/863,624 US6046180A (en) 1996-06-17 1997-05-27 NAALADase inhibitors
US08/858,985 US6025344A (en) 1996-06-17 1997-05-27 Certain dioic acid derivatives useful as NAALADase inhibitors
US08/884,479 US6017903A (en) 1996-09-27 1997-06-27 Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors

Publications (1)

Publication Number Publication Date
ID18382A true ID18382A (en) 1998-04-02

Family

ID=27578904

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP972763A ID18382A (en) 1996-09-27 1997-08-08 PHARMACEUTICAL COMPOSITION AND METHODS FOR TREATMENT OF COMPULSIF DISORDERS USING NAALADASE INHIBITORS

Country Status (6)

Country Link
EP (1) EP0949922A1 (en)
JP (1) JP2002514185A (en)
AU (1) AU4151897A (en)
CA (1) CA2264158A1 (en)
ID (1) ID18382A (en)
WO (1) WO1998013044A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054444A (en) * 1997-04-24 2000-04-25 Guilford Pharmaceuticals Inc. Phosphonic acid derivatives
US5977090A (en) * 1996-09-27 1999-11-02 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors
US6071965A (en) * 1996-06-17 2000-06-06 Guilford Pharmaceuticals Inc. Phosphinic alkanoic acid derivatives
US5962521A (en) * 1997-04-04 1999-10-05 Guilford Pharmaceuticals Inc. Hydroxamic acid derivatives
ID20347A (en) * 1997-05-27 1998-12-03 Guilford Pharm Inc INHIBITOR ACTIVITIES OF NAALADASE ENZYMES
WO1998053812A1 (en) * 1997-05-27 1998-12-03 Guilford Pharmaceuticals Inc. Inhibitors of naaladase enzyme activity
US6458775B1 (en) * 1998-07-06 2002-10-01 Guilford Pharmaceutical Inc. NAALADase inhibitors useful as pharmaceutical compounds and compositions
CA2658200A1 (en) * 1998-07-06 2000-01-13 Mgi Gp, Inc. Naaladase inhibitors useful as pharmaceutical compounds and compositions
US6228888B1 (en) * 1999-07-01 2001-05-08 Guilford Pharmaceuticals Inc. Methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors
AU781218B2 (en) 1999-08-16 2005-05-12 Revaax Pharmaceuticals, Llc Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of behavioral diseases
US6313159B1 (en) * 1999-08-20 2001-11-06 Guilford Pharmaceuticals Inc. Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors
US7528173B2 (en) * 2002-03-21 2009-05-05 Schering Aktiengesellshaft Plasma carboxypeptidase B inhibitors
WO2004078180A2 (en) * 2003-03-03 2004-09-16 Guilford Pharmaceuticals Inc. Naaladase inhibitors for treating opioid tolerance
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP5259970B2 (en) * 2007-03-30 2013-08-07 学校法人九州文化学園 Drug dependence treatment
EP2338892A1 (en) 2009-12-18 2011-06-29 Bayer Schering Pharma Aktiengesellschaft Prostate specific membrane antigen inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5500420A (en) * 1993-12-20 1996-03-19 Cornell Research Foundation, Inc. Metabotropic glutamate receptor agonists in the treatment of cerebral ischemia

Also Published As

Publication number Publication date
EP0949922A1 (en) 1999-10-20
WO1998013044A1 (en) 1998-04-02
AU4151897A (en) 1998-04-17
CA2264158A1 (en) 1998-04-02
JP2002514185A (en) 2002-05-14

Similar Documents

Publication Publication Date Title
ZA977090B (en) Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors
ID18382A (en) PHARMACEUTICAL COMPOSITION AND METHODS FOR TREATMENT OF COMPULSIF DISORDERS USING NAALADASE INHIBITORS
BR9611137A (en) Compositions and methods for oral distribution of pharmaceutical agents
ID21332A (en) METHODS AND COMPOSITIONS FOR TREATMENT AND PREVENTION OF HYPERURICEMIA
FI971969A0 (en) Compositions and method of use for the treatment of hemorrhoids
ES2178157T3 (en) TREATMENT OF ARRITMIAS THROUGH THE INHIBITION OF A MULTIFUNCTIONAL KINASE PROTEIN DEPENDENT ON CALCIUM / CALMODULIN.
NZ333234A (en) Phosphinyl derivatives useful as naaladase inhibitors and pharmaceutical compositions thereof for treating prostate diseases
BR1100403A (en) Compound and pharmaceutical composition of cox-2 inhibitors
NO982809D0 (en) Drugs of thrombin inhibitors
NO982311D0 (en) Compositions and methods for the prevention and treatment of oral mucositis
HUP0000210A3 (en) Heterocyclic compounds as metalloprotease inhibitors and use of them for producing pharmaceutical compisitions
IL128217A0 (en) Phosphatase inhibitors and methods of use thereof
HU9700602D0 (en) New inhibitors of bone-resorption and vitronectine-receptor-antagonists
NO972972L (en) Compositions for the treatment of dermatological disorders and methods for their use
ID25667A (en) METHOD AND EQUIPMENT FOR WIDEBAND PREDISTORATION OF LINIERSATION
ZA988017B (en) Parp inhibitors pharmaceutical compositions comprising same and methods of using same
ZA977087B (en) Methods of cancer treatment using naaladase inhibitors
HUP9902105A3 (en) Pharmaceutical angiostatic dipeptide compositions and methods of use thereof
AUPO727097A0 (en) Method of treatment of hepatoma and pharmaceutical compositions for use therein
DE69828345D1 (en) Cross-correlation method and device for suppressing the effects of multiple scattering
EE9800234A (en) Method of treatment and pharmaceutical composition
AU3005997A (en) Inhibitors of picornavirus 3c proteases and methods for their use and preparation
PT927183E (en) SPIROCYLIC INHIBITORS OF METALOPROTEASES
ID28460A (en) COMPOSITION AND METHODS FOR TREATMENT AND PREVENTION OF BONE DISEASE USING TOCOTRIENOL
ID29547A (en) METHODS AND COMPOSITIONS FOR TUBERCULOSIS PREVENTION AND TREATMENT